For help on how to get the results you want, see our search tips.
6207 results
Medicine
Orphan designations Remove Orphan designations filter
Periodic safety update report single assessments Remove Periodic safety update report single assessments filter
Paediatric investigation plans Remove Paediatric investigation plans filter
Categories
Human Remove Human filter
-
List item
Orphan designation: Tadekinig alfa for: Treatment of haemophagocytic lymphohistiocytosis (updated)
Date of first decision: 14/10/2016, Positive, Last updated: 19/02/2021 -
List item
Orphan designation: Recombinant fusion protein consisting of a modified form of the extracellular domain of human activin receptor IIB linked to the human IgG1 Fc domain (luspatercept) for: Treatment of beta thalassaemia intermedia and major (updated)
Date of first decision: 29/07/2014, Positive, Last updated: 18/02/2021 -
List item
Orphan designation: Recombinant fusion protein consisting of a modified form of the extracellular domain of human activin receptor IIB linked to the human IgG1 Fc domain (luspatercept) for: Treatment of myelodysplastic syndromes (updated)
Date of first decision: 22/08/2014, Positive, Last updated: 18/02/2021 -
List item
Orphan designation: Luspatercept for: Treatment of myelofibrosis (updated)
Date of first decision: 28/02/2020, Positive, Last updated: 18/02/2021 -
List item
Orphan designation: 5-(Ethylsulfonyl)-2-(naphthalen-2-yl)benzo[d]oxazole (ezutromid) for: Treatment of Duchenne muscular dystrophy (updated)
Date of first decision: 04/12/2008, Withdrawn, Last updated: 10/02/2021 -
List item
Orphan designation: human anti-promyostatin monoclonal antibody (apitegromab) for: Treatment of spinal muscular atrophy (updated)
Date of first decision: 14/12/2018, Positive, Last updated: 09/02/2021 -
List item
Orphan designation: Autologous CD4+ and CD8+ T cells expressing a CD19-specific chimeric antigen receptor (lisocabtagene maraleucel) for: Treatment of diffuse large B-cell lymphoma (updated)
Date of first decision: 17/07/2017, Positive, Last updated: 09/02/2021 -
List item
Orphan designation: Autologous CD4+ and CD8+ T cells expressing a CD19-specific chimeric antigen receptor (lisocabtagene maraleucel) for: Treatment of follicular lymphoma (updated)
Date of first decision: 25/05/2018, Positive, Last updated: 09/02/2021 -
List item
Orphan designation: Lisocabtagene maraleucel for: Treatment of primary mediastinal large B-cell lymphoma (updated)
Date of first decision: 19/11/2018, Positive, Last updated: 09/02/2021 -
List item
Orphan designation: Human monoclonal antibody against Pseudomonas aeruginosa IATS-O1 for: Treatment of pneumonia caused by serotype O1 Pseudomonas aeruginosa (updated)
Date of first decision: 28/01/2010, Withdrawn, Last updated: 03/02/2021 -
List item
Orphan designation: RNA, [P-deoxy-P-(dimethylamino)] (2',3'-dideoxy-2',3'-imino-2',3'-seco) (2'a→5') (C-m5U-m5U-A-C-A-G-G-C-m5U-C-C-A-A-m5U-A-G-m5U-G-G-m5U-C-A-G-m5U), 5' [P-[4-[[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]carbonyl]-1-piperazinyl]-N,N-dimethylaminophosphonamidate], 3'-[2'a-[N2-acetyl-L-arginyl-6-aminohexanoyl-L-arginyl-L-arginyl-β-alanyl-L-arginyl-L-arginyl-6-aminohexanoyl-L-arginyl-L-arginyl-β-alanyl-L-arginyl-6-aminohexanoyl-β-alanyl], octahydrochloride for: Treatment of Duchenne muscular dystrophy (updated)
Date of first decision: 02/02/2010, Withdrawn, Last updated: 03/02/2021 -
List item
Orphan designation: Sodium thiosulfate for: Treatment of calciphylaxis (updated)
Date of first decision: 23/02/2011, Withdrawn, Last updated: 03/02/2021 -
List item
Orphan designation: Adeno-associated viral vector serotype 8 containing the human UGT1A1 gene (volrubigene ralaparvovec) for: Treatment of Crigler-Najjar syndrome (updated)
Date of first decision: 18/11/2016, Withdrawn, Last updated: 03/02/2021 -
List item
Orphan designation: Heparin-activated recombinant human fibroblast growth factor 1 (on a biodegradable device made from alpha-calcium sulfate hemihydrate) for: Treatment of traumatic spinal cord injury (updated)
Date of first decision: 27/07/2010, Withdrawn, Last updated: 03/02/2021 -
List item
Orphan designation: Poly(oxy-1,2-ethanediyl), alpha-hydro-omega-hydroxy-,15,15'-diester with N-acetyl-L-isoleucyl-L-cysteinyl-L-valyl-1-methyl-L-tryptophyl-L-glutaminyl-L-alpha-aspartyl-L-tryptophylglycyl-L-alanyl-L-histidyl-L-arginyl-L-cysteinyl-L-threonyl-2-[2-(2-aminoethoxy)ethoxy]acetyl-N6-carboxy-L-lysinamide cyclic (2.fwdarw.12)-(disulfide); where two identical synthetic peptide domains are covalently linked at the ends of the polyethylene glycol chain (pegcetacoplan) for: Treatment of C3 glomerulopathy (updated)
Date of first decision: 21/08/2019, Positive, Last updated: 03/02/2021 -
List item
Orphan designation: 2-isopropyl-3H-naphtho[1,2-d]imidazole-4,5-dione for: Treatment of mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes (updated)
Date of first decision: 12/12/2017, Positive, Last updated: 03/02/2021 -
List item
Orphan designation: ciclosporin for: Treatment of moderate and severe closed traumatic brain injury (updated)
Date of first decision: 01/10/2010, Positive, Last updated: 03/02/2021 -
List item
Orphan designation: 2-Hydroxyoleic acid for: Treatment of glioma (updated)
Date of first decision: 27/10/2011, Positive, Last updated: 03/02/2021 -
List item
Orphan designation: (1S,3S)-3-amino-4-(difluoromethylene) cyclopentanecarboxylic acid hydrochloride for: Treatment of West syndrome (updated)
Date of first decision: 09/02/2012, Withdrawn, Last updated: 03/02/2021 -
List item
Orphan designation: Rovalpituzumab tesirine for: Treatment of small cell lung cancer (updated)
Date of first decision: 30/05/2016, Withdrawn, Last updated: 03/02/2021 -
List item
Orphan designation: Oxalobacter formigenes strain HC-1 for: Treatment of primary hyperoxaluria (updated)
Date of first decision: 17/02/2006, Positive, Last updated: 02/02/2021 -
List item
Orphan designation: Oxalobacter formigenes strain HC-1 for: Treatment of short bowel syndrome (updated)
Date of first decision: 15/10/2014, Positive, Last updated: 02/02/2021 -
List item
Orphan designation: Somapacitan for: Treatment of growth hormone deficiency (updated)
Date of first decision: 24/08/2018, Positive, Last updated: 01/02/2021 -
List item
Orphan designation: pemigatinib for: Treatment of myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRA, PDGFRB, or FGFR1, or with PCM1-JAK (updated)
Date of first decision: 17/10/2019, Positive, Last updated: 01/02/2021 -
List item
Orphan designation: Clofazimine for: Treatment of nontuberculous mycobacterial lung disease
Date of first decision: 21/08/2019, Positive, Last updated: 28/01/2021